Tyrosine kinase inhibitors (TKIs) have significantly transformed the management and prognosis of patients with lung adenocarcinoma (LUAD) harboring epidermal growth factor receptor (EGFR) sensitizing mutations [1–3]. Here, EGFR is linked to lung adenocarcinoma.